Nutropin AQ ( DrugBank: - )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
78	下垂体前葉機能低下症	7
193	プラダー・ウィリ症候群	1
299	嚢胞性線維症	3

78. 下垂体前葉機能低下症

臨床試験数 : 494 / 薬物数 : 385 - (DrugBank : 49) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 100

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02311894 (ClinicalTrials.gov)	March 31, 2015	4/12/2014	A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] ...	A Phase IV, Multicenter, Open-Label Study of the Immunogenicity of Nutropin AQ® V1.1 [Somatropin (rD ...	Growth Hormone Deficiency	Drug: Somatropin	Genentech, Inc.	NULL	Completed	3 Years	14 Years	All	82	Phase 4	United States
2	NCT01243892 (ClinicalTrials.gov)	November 2010	17/11/2010	A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device	A Phase IV, Open Label, Multicenter, Case-controlled Study of Growth in Patients Using the Nutropin ...	Growth Hormone Deficiency	Device: NuSpin;Drug: Somatropin	Genentech, Inc.	NULL	Terminated	2 Years	14 Years	All	18	Phase 4	United States
3	EUCTR2010-019735-35-FR (EUCTR)	14/06/2010	30/04/2010	Effets du traitement substitutif par hormone de croissance chez les patients présentant un déficit s ...	Effets du traitement substitutif par hormone de croissance chez les patients présentant un déficit s ...	Déficit somatotrope de l'adulte consécutif à un traumatisme crânien MedDRA version: 12.1;Level: LLT; ...	Trade Name: Nutropin Aq Product Name: NutropinAq	CHU Amiens	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France
4	NCT00837863 (ClinicalTrials.gov)	March 2009	2/2/2009	Study of Weekly ALTU-238 Compared With Daily Nutropin AQin Prepubertal Children With Growth Hormone ...	A Twelve Month, Phase II, Randomized, Open-Label, Multi-Center, Dose-Ranging Study of Weekly ALTU-23 ...	Growth Hormone Deficiency	Drug: Somatropin	Altus Pharmaceuticals	NULL	Recruiting	3 Years	13 Years	Both	36	Phase 2	United States
5	NCT00212758 (ClinicalTrials.gov)	January 2005	14/9/2005	A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 ...	IGF-1 Generation Test in Children With Chronic Kidney Disease	Kidney Failure, Chronic;Growth Hormone Deficiency	Drug: Nutropin AQ	Oregon Health and Science University	Genentech, Inc.	Completed	2 Years	18 Years	All	17	Phase 4	United States
6	NCT00140413 (ClinicalTrials.gov)	December 2004	31/8/2005	Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia	Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia	Growth Hormone Deficiency;Septo-Optic Dysplasia;Hypopituitarism	Drug: Nutropin AQ	Children's Hospital Los Angeles	Genentech, Inc.	Completed	N/A	5 Years	All	20	Phase 4	United States
7	NCT00134420 (ClinicalTrials.gov)	February 2001	22/8/2005	Growth Hormone and Chromosome 18q- and Abnormal Growth	Growth Hormone Trial for Children With 18q- and Abnormal Growth	Loss of Chromosome 18q;Growth Hormone Deficiency	Drug: Nutropin AQ;Procedure: Arginine and Clonidine Stimulation Testing;Procedure: Growth Factors La ...	The University of Texas Health Science Center at San Antonio	South Texas Veterans Health Care System;Genentech, Inc.	Completed	N/A	18 Years	Both	20	Phase 3	United States

First Previous1Next Last

先頭へ

193. プラダー・ウィリ症候群

臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00444964 (ClinicalTrials.gov)	April 2005	6/3/2007	Growth Hormone Use in Adults With Prader-Willi Syndrome	Growth Hormone Use in Adults With Prader-Willi Syndrome	Prader-Willi Syndrome	Drug: Nutropin AQ	Children's Mercy Hospital Kansas City	NULL	Recruiting	16 Years	60 Years	Both	10	Phase 3	United States

First Previous1Next Last

299. 嚢胞性線維症

臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00803179 (ClinicalTrials.gov)	November 2008	4/12/2008	Growth Hormone Therapy for Wasting in Cystic Fibrosis	Growth Hormone Therapy for Wasting in Cystic Fibrosis	Cystic Fibrosis	Drug: Nutropin AQ	University of Massachusetts, Worcester	NULL	Terminated	18 Years	N/A	All	5	Phase 1	United States
2	NCT00079742 (ClinicalTrials.gov)	September 2003	11/3/2004	A Study to Evaluate Nutropin AQfor the Treatment of Growth Restriction in Children With Cystic Fibro ...	A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety and Efficacy of Nutr ...	Cystic Fibrosis	Drug: Nutropin AQ [somatropin (DNA origin) injection]	Genentech, Inc.	NULL	Completed	5 Years	13 Years	Both	68	Phase 2	United States
3	NCT00256555 (ClinicalTrials.gov)	February 2000	17/11/2005	Growth Hormone Treatment Study in Children With Cystic Fibrosis	GROWTH HORMONE USE IN CYSTIC FIBROSIS - A MULTICENTER STUDY	Cystic Fibrosis	Drug: Nutropin AQ	University of Texas Southwestern Medical Center	Genentech, Inc.	Withdrawn	5 Years	12 Years	All	0	Phase 2/Phase 3	NULL

First Previous1Next Last

先頭へ